Helsinki heart study: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) (Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}}; {{AE}} {{Rim}} ==Official Title== ==Objective== ==Sponsor== ==Timeline== {| class="wikitable" border="1" style="backgro...") |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{Rim}} | {{CMG}}; {{AE}} {{Rim}} | ||
==Overview== | |||
== | The Helsinki Heart Study (HHS) is a randomized double-blind trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfifibrozil. | ||
==Study Description== | ==Study Description== | ||
| Line 32: | Line 13: | ||
|- | |- | ||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description''' | | Colspan="2" style="background:Gainsboro" align="center"|'''Study Description''' | ||
|- | |- | ||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design''' | | Colspan="2" style="background:Gainsboro" align="center"|'''Study Design''' | ||
|- | |- | ||
| '''Allocation'''|| | | '''Allocation'''||Randomized | ||
|- | |- | ||
| '''Endpoint'''|| | | '''Endpoint'''|| Coronary heart disease | ||
|- | |- | ||
| '''Masking'''|| Double blind | |||
| '''Masking'''|| | |||
|- | |- | ||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | | Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | ||
|- | |- | ||
| '''Primary Purpose'''|| | | '''Primary Purpose'''||Prevention | ||
|- | |- | ||
| '''Condition'''|| | | '''Condition'''||Primary dyslipidemia | ||
|- | |- | ||
| '''Intervention'''|| | | '''Intervention'''||Gemfibrosil <br> Placebo | ||
|- | |- | ||
| '''Population Size'''||4081 subjects | |||
| '''Population Size'''|| | |||
|- | |- | ||
|} | |} | ||
<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number #.</span> | <span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number #.</span> | ||
==Publications== | ==Publications== | ||
===Results=== | ===Results=== | ||
==References== | ==References== | ||
Revision as of 00:25, 19 August 2014
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
Helsinki heart study On the Web |
|
American Roentgen Ray Society Images of Helsinki heart study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The Helsinki Heart Study (HHS) is a randomized double-blind trial that assessed the primary cardiovascular preventive effect of elevation in HDL and decrease in non-HDL cholesterol with gemfifibrozil.
Study Description
| Study Description | |
| Study Design | |
| Allocation | Randomized |
| Endpoint | Coronary heart disease |
| Masking | Double blind |
| Study Details | |
| Primary Purpose | Prevention |
| Condition | Primary dyslipidemia |
| Intervention | Gemfibrosil Placebo |
| Population Size | 4081 subjects |
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number #.